CarMax, Inc (KMX) Stock Price Today
Aura AI Summary
Key Stats
- $8.98BMarket Cap
- -Volume
- Consumer CyclicalSector
- $64.2252W High
- $30.8852W Low
- -Typical Hold Time
- $27.49BEnterprise Value
- -Div Yield
- -Trading Activity
Track CarMax, Inc (KMX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CarMax, Inc has traded between a low of $30.88 and a high of $64.22, highlighting its annual price range. Buy and sell CarMax, Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Most Recent News
Core Scientific director Elizabeth Crain buys 6,000 shares, signaling confidence in the company.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data shifts to AI data centers, signals undervaluation and insider confidence
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Pharvaris stock jumps after positive HAE drug trial and Oppenheimer raises price target to $75
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.